Voyager Therapeutics Inc
NASDAQ:VYGR

Watchlist Manager
Voyager Therapeutics Inc Logo
Voyager Therapeutics Inc
NASDAQ:VYGR
Watchlist
Price: 4.03 USD -1.71% Market Closed
Market Cap: $224.1m

Operating Margin

-450.2%
Current
Declining
by 370.4%
vs 3-y average of -79.9%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-450.2%
=
Operating Income
$-141m
/
Revenue
$31.3m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-450.2%
=
Operating Income
$-141m
/
Revenue
$31.3m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Voyager Therapeutics Inc
NASDAQ:VYGR
221.7m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.4B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
169B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.8B USD
Loading...

Market Distribution

Lower than 91% of companies in the United States of America
Percentile
9th
Based on 14 112 companies
9th percentile
-450.2%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Voyager Therapeutics Inc
Glance View

Market Cap
224.1m USD
Industry
Biotechnology

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 101 full-time employees. The company went IPO on 2015-11-11. Its gene therapy platforms enable it to engineer, optimize, manufacture, and deliver its adeno-associated virus (AAV)-based gene therapies. The company is identifying AAV capsids, the outer viral protein shells that enclose genetic material of a virus payload. The company has developed a AAV capsid discovery platform, Tropism Redirection of AAV by Cell Type-Specific Expression of RNA (TRACER) to facilitate the selection of AAV capsids with blood brain barrier (BBB) crossing and cell-specific transduction properties for therapeutic applications. Its gene therapy programs include treatment programs for Huntington's disease, monogenic amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), and various diseases linked to GBA1 mutations, including Parkinson's disease, Lewy body dementia and Gaucher's disease. The company also focuses on tauopathies and indications in neuro-oncology.

VYGR Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-450.2%
=
Operating Income
$-141m
/
Revenue
$31.3m
What is Voyager Therapeutics Inc's current Operating Margin?

The current Operating Margin for Voyager Therapeutics Inc is -450.2%, which is below its 3-year median of -79.9%.

How has Operating Margin changed over time?

Over the last 3 years, Voyager Therapeutics Inc’s Operating Margin has decreased from -29.3% to -450.2%. During this period, it reached a low of -450.2% on Oct 30, 2025 and a high of 48.9% on Mar 31, 2023.

Back to Top